|Arix Bioscience||Investment Director||United Kingdom|
Agnostic or pure players in the biotech sector: Who is becoming prominent in the early-stage financing rounds?
Jonathan specialises in biotechnology investments. He currently sits on the board of Artios Pharma. Prior to joining Arix Bioscience, Jonathan spent five years at Imperial Innovations, where he was a Principal in the Healthcare Ventures team. He was involved with the formation and investment in a number of early stage companies, including Inivata, Auspherix, Abingdon Health, Cell Medica, and Psioxus. Jonathan also worked at MRC Technology, sourcing and evaluating new small molecule and antibody drug discovery projects.
He has a first class degree in biology from the University of Oxford, a PhD in Molecular Medicine from UCL, carried out postdoctoral research at the Cancer Research UK London Research Institute (now Crick Institute), and published research in journals including PNAS, New England Journal of Medicine, and Nature Genetics. Jonathan also has an MBA with distinction from Imperial College.